Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapySource: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004
Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006
Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
The impact of colonization with therapy-resistant pathogens on the survival rate after lung transplantation (LUTX) in cystic fibrosis (CF) Source: Virtual Congress 2021 – Optimising outcomes of lung transplantation: how to move forward? Year: 2021
The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009
Feasibility study of an intervention to increase treatment adherence in children with cystic fibrosis (CF) Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Effect of recurrent growth of aspergillus on lung function in paediatric population with cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011
Antibiotic treatment of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 188-202 Year: 2014
Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Long-term course of lung clearance index among patients with cystic fibrosis Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment Year: 2020
Dysregulation of systemic and local immune response in cystic fibrosis patients with chronic P. aeruginosa infection Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004
Predictors of eradication failure at first isolation of MRSA in cystic fibrosis patients Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020